246 related articles for article (PubMed ID: 32504402)
1. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
[TBL] [Abstract][Full Text] [Related]
2. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
[TBL] [Abstract][Full Text] [Related]
3. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
4. The genetic signatures of pediatric high-grade glioma: no longer a one-act play.
Diaz AK; Baker SJ
Semin Radiat Oncol; 2014 Oct; 24(4):240-7. PubMed ID: 25219808
[TBL] [Abstract][Full Text] [Related]
5. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
[TBL] [Abstract][Full Text] [Related]
6. Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG).
Bailey CP; Figueroa M; Mohiuddin S; Zaky W; Chandra J
Bioengineering (Basel); 2018 Oct; 5(4):. PubMed ID: 30340362
[TBL] [Abstract][Full Text] [Related]
7. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
Stitzlein LM; Adams JT; Stitzlein EN; Dudley RW; Chandra J
J Exp Clin Cancer Res; 2024 Jan; 43(1):12. PubMed ID: 38183103
[TBL] [Abstract][Full Text] [Related]
8. Pediatric hemispheric high-grade glioma: targeting the future.
Coleman C; Stoller S; Grotzer M; Stucklin AG; Nazarian J; Mueller S
Cancer Metastasis Rev; 2020 Mar; 39(1):245-260. PubMed ID: 31989507
[TBL] [Abstract][Full Text] [Related]
9. Advances on Epigenetic Drugs for Pediatric Brain Tumors.
Skouras P; Markouli M; Strepkos D; Piperi C
Curr Neuropharmacol; 2023; 21(7):1519-1535. PubMed ID: 36154607
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
11. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
12. Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
Pal S; Kozono D; Yang X; Fendler W; Fitts W; Ni J; Alberta JA; Zhao J; Liu KX; Bian J; Truffaux N; Weiss WA; Resnick AC; Bandopadhayay P; Ligon KL; DuBois SG; Mueller S; Chowdhury D; Haas-Kogan DA
Cancer Res; 2018 Jul; 78(14):4007-4021. PubMed ID: 29760046
[TBL] [Abstract][Full Text] [Related]
13. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
[TBL] [Abstract][Full Text] [Related]
14. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
15. Emerging Epigenetic Therapies for Brain Tumors.
Kukreja L; Li CJ; Ezhilan S; Iyer VR; Kuo JS
Neuromolecular Med; 2022 Mar; 24(1):41-49. PubMed ID: 34677796
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
17. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
19. Histone H3K9 methyltransferase SETDB1 overexpression correlates with pediatric high-grade gliomas progression and prognosis.
Klonou A; Korkolopoulou P; Giannopoulou AI; Kanakoglou DS; Pampalou A; Gargalionis AN; Sarantis P; Mitsios A; Sgouros S; Papavassiliou AG; Piperi C
J Mol Med (Berl); 2023 Apr; 101(4):387-401. PubMed ID: 36811655
[TBL] [Abstract][Full Text] [Related]
20. [Pediatric Hemispheric Glioma].
Nakano Y; Ichimura K; Sakamoto H
No Shinkei Geka; 2022 Jan; 50(1):122-131. PubMed ID: 35169092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
